Sign inJoin waitlistJoin the waitlist

Kami Maddocks

Chief Medical Officer, James Cancer Hospital and Solove Research Institute · Ohio State University Hospital

Credentials: · · · · ·

History

Ohio State University Hospital
Present

Ohio State University College of Medicine
2008–2011
Internal Medicine
Mayo Clinic
2005–2008
University of South Dakota Sanford School of Medicine
2001–2005

Research

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Blood · 2013 · 699 citations
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
JAMA Oncology · 2015 · First of 21 authors · 524 citations
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
The Lancet Oncology · 2020 · Last of 17 authors · 466 citations

JB
John Byrd
51 papers
David Bond
44 papers · 4 as a fellow
JJ
Jeffrey Jones
37 papers
Jennifer Woyach
33 papers
Robert Baiocchi
29 papers
Beth Christian
28 papers
LA
Leslie Andritsos
28 papers
YS
Yazeed Y Sawalha
28 papers
JF
Joseph Flynn
27 papers
Jonathon Cohen
24 papers · 1 as a fellow
Kristie Blum
24 papers
Samantha Jaglowski
24 papers

Grants

Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $70.2K · Ohio State University
1997–2031

Clinical trials

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
Principal investigator · Completed · Phase 1, Phase 2
Ohio State University Comprehensive Cancer Center
2018–2021
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Principal investigator · Completed · Phase 1
Kami Maddocks
2017–2019
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Principal investigator · Completed · Phase 1
Kami Maddocks, MD
2014–2019
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Principal investigator · Active not recruiting · Phase 1
Kami Maddocks, MD
2014–2026